Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2260 - Prognostic factors and survival in germ cell cancer (GCC) patients treated with bleomycin, etoposide, and cisplatin (BEP): A population-based study


09 Oct 2016


Poster display


Maria Kier


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


M.G.G. Kier1, J. Lauritsen1, M.S. Mortensen1, M. Bandak2, K.K. Andersen3, M.K. Hansen3, M. Agerbaek4, N.V. Holm5, S.O. Dalton6, C. Johansen6, G. Daugaard1

Author affiliations

  • 1 Department Of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 2 Department Of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen/DK
  • 3 Unit Of Statistics, Danish Cancer Society Research Center, Copenhagen/DK
  • 4 Department Of Oncology, Aarhus University Hospital, Aarhus C/DK
  • 5 Department Of Oncology, Odense University Hospital, Odense C/DK
  • 6 Unit Of Survivorship, Danish Cancer Society Research Center, 2100 - Copenhagen/DK


Abstract 2260


The prognostic classification applied in disseminated GCC was established in 1997, based on patients treated with cisplatin containing regimens. Only a minority of the patients were treated with BEP. We aimed to estimate overall survival (OS) and propose new prognostic factors for GCC patients treated with first line BEP.


From the nationwide Danish Testicular Cancer database, a total of 1889 BEP treated patients were included, divided in 440 seminoma GCC (SGCC) patients and 1449 with non-seminoma GCC (NSGCC). The median follow-up was 14 years. We evaluated the following factors for 3-year progression-free survival: age, non-pulmonary visceral metastases, pulmonary metastases, smoking status, primary site, and level of tumor markers.


For SGCC, the 5-year OS was 92% and 68% for patients in the good and intermediate prognostic group; for NSGCC, the 5-year OS was 96%, 85%, and 65% for patients in the good, intermediate, and poor prognostic group, respectively. For SGCC patients, we found the following adverse prognostic factors not included in the current classification: older age (hazard ratio (HR), 1.44; 95% confidence interval (CI) 1.17–1.78 per 10 years), pulmonary metastases (HR, 2.80; 95% CI 1.35–5.82), and lactate dehydrogenase > 1.5 times the upper limit of normal (HR, 2.06; 95% CI 1.19–3.57). For NSGCC patients, we identified older age (HR, 1.45; 95% CI 1.29–1.64 per 10 years) and pulmonary metastases (HR, 2.15; 95% CI 1.61–2.87) as possible additional adverse prognostic factors.


Survival for all prognostic groups has increased since publication of the IGCCCG classification. Based on a nationwide cohort of patients treated with BEP, we have identified new possible prognostic factors not included in the current prognostic classification for patients with disseminated GCC. The findings should be validated in larger cohorts.

Clinical trial identification

Legal entity responsible for the study

Rigshospitalet, Copenhagen University Hospital


Danish Cancer Society Anna and Preben Simonsens Foundation


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings